跳到主要内容
Rallybid

已截止

全国感染和脓毒症审计 – 急症NHS医疗机构

Healthcare Quality Improvement Partnership已就“全国感染和脓毒症审计 – 急症NHS医疗机构”发布此招标,现已不再接受新的投标。

此招标已不再接受新的投标。 类似的进行中招标

用通俗的话说,这项招标是什么?

全国感染和脓毒症审计 – 急症NHS医疗机构

这份合同旨在为英格兰和威尔士的NHS医院,进行一项关于严重感染和脓毒症的全新全国临床审计。目标是收集感染和脓毒症护理的数据,以发现差异并随着时间推动改进。审计将专注于护理的早期阶段,这对于有效管理严重感染和迅速治疗脓毒症至关重要。

采购方有什么要求?

  • 为英格兰和威尔士的NHS资助护理提供为期三年的审计服务。
  • 提交的成本预算最高不得超过£1,146,300.00(不含增值税)。
  • 确保投标金额不超过规定的预算上限。
  • 审计工作需与NHS England脓毒症现代服务框架和威尔士NHS国家病人安全计划等主要医疗倡议紧密配合。

这项招标适合哪些人?

此机会适合在临床审计方面具有专业知识的机构,特别是那些与急症医院环境中严重感染和脓毒症管理相关的机构。

机器翻译由 AI 翻译,方便你阅读。投标必须使用采购方的语言(英语)撰写。原文列在下方。 公告全文

同类招标的过往中标记录说明了什么?

  • 同类招标平均每项约有 2.4 份投标(19 项中标记录载有数目)。
  • 半数同类合同的中标金额介于 £5,427,055 至 £14,496,441,中位数为 £11,155,000。

根据过去 36 个月 33 项中标记录:相同工种、相同地区、金额相近。可信程度:中。以上仅反映过往情况,并非预测结果。 中标数据

谁赢得了这项招标,金额是多少?

此招标尚未公布中标结果。

公告全文

原文(English)

National Infection and Sepsis Audit – Acute NHS settings

The contract for the Infection and Sepsis Audit - Acute care settings (NISA-Acute) will initially be delivered for NHS-funded care in England and Wales for a period of three years, at a maximum total budget of up to £ 1,146,300.00 excl VAT and £1,375,560.00 with VAT. Bids exceeding these limits will be rejected. All pricing submissions must be in regard to this 'core' value, and not inclusive of any extension costs or aspirational intent costs, i.e. Please only submit a cost schedule up to the maximum core value of £ 1,146,300.00 excl VAT and £1,375,560.00 with VAT. The maximum budget ‘core’ value excludes the potential two year extension and aspirational intent as described in section 14.3 of Annex A - Service Specification. Please note, there is no commitment by the Authority at this stage to include any of the below aspirational intent. Taking this aspirational intent into account, including the possibility that a contract extension may be offered for an additional 24 months, the potential ceiling value is £8,988,606.00 GBP including VAT. This is a new national clinical audit for severe infection and sepsis in acute NHS hospital settings. The aim is to provide benchmarked infection and sepsis care data to identify variation and drive improvement over time. Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. While it is an unusual complication of developing an infection, it can be triggered by any infection. When people die from an infection, it is most commonly due to sepsis. Sepsis is complex and hard to diagnose, with no single test and symptoms that overlap with other conditions (NHS England Modern Service Framework, 2026) Severe infections may lead to the development of sepsis, particularly in at-risk groups, and are one of the most common reasons for emergency admission to hospital. Both infection and sepsis are major causes of morbidity and mortality in the UK, and costly to the NHS and wider economy: In 2025 there were over 23,000 deaths involving sepsis (Office for National Statistics). Patients and carers who we engaged with as part of specification development told us of long-term impacts that some sepsis survivors experience, from reduced mobility and cognitive difficulties, to loss of limbs or vision impairments. Each year, the NHS in England spends over £1billion on sepsis care, and over £6.5billion on infection care. Wider economic costs are estimated at £10-15billion annually (York Health Economics Consortium, 2017). 1,300 clinical negligence claims were made regarding sepsis from 2020/21 to 2024/25, costing £65.3m in litigation. Most claims relate to delays and failures in treatment and diagnosis. Several major healthcare initiatives have been launched to help improve care related to sepsis and severe infection, including: NHS England’s sepsis Modern Service Framework (MSF), which aims to reduce death, life-threatening complications and long-term impact from sepsis and severe infection by at least 25% by 2035, as well as reducing health inequalities (published July 2026). NHS England’s National Improvement Programme for ‘Optimising the acute management of sepsis’ (as part of the MSF activities). The National Patient Safety Plan for NHS Wales 2026-2031, which includes sepsis care. The UK Anti-Microbial Resistance (AMR) National Action Plan, which pledges to strengthen infection prevention and control (IPC) and antimicrobial stewardship (AMS) in health and social care settings New NICE guidelines for recognition, diagnosis and early management of suspected sepsis, published in November 2025 (NG253-NG255) Establishing the NISA-Acute audit is a key ambition of the NHS England sepsis MSF, and the audit will be expected to align closely with all the initiatives listed above. The audit funders have selected ‘early stages of care’ as the initial priority for this audit because this is a critical point for effective severe infection management and the swift identification and treatment of sepsis. Prompt, effective treatment is vital to improving outcomes, and both Prevention of Future Death (PFD) reports and Health Services Safety Investigations Body (HSSIB) investigations have highlighted opportunities to improve care in this area.

文件

通过邮件接收这些招标

每天一封邮件,列出你所选行业和地区的新招标。无需账户或密码。

我们会先通过邮件向你发送确认链接。在你使用链接之前,不会发送任何其他内容。 隐私声明

快速解答

这项招标什么时候截止?

已于2026年10月27日截止。

这份合同价值多少?

采购方估计金额为£8,988,606。

采购方是谁?

采购方是Healthcare Quality Improvement Partnership。

同类招标通常有多少企业投标?

同类招标平均每项约有 2.4 份投标(19 项中标记录载有数目)。 根据过去 36 个月 33 项中标记录:相同工种、相同地区、金额相近。可信程度:中。以上仅反映过往情况,并非预测结果。

类似的进行中招标